Mismatch repair protein MLH1 and MSH2 expression was retained, molecular MSI testing (Bethesda markers plus the mononucleotide marker CAT25 (21) additionally confirmed a microsatellite-stable tumor. This evidence concerns the gene MLH1 and neoplasm.